The new medicare part D prescription drug benefit: An estimation of its effect on prescription drug costs in a medicare population with atrial fibrillation

Carmella Evans-Molina, Susan Regan, Lori E. Henault, Elaine M. Hylek, Gregory R. Schwartz

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVES: To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients. DESIGN: Inception cohort study. SETTING: An academic medical center. PARTICIPANTS: Four hundred seventy-two patients aged 65 and older who were followed as part of a larger study assessing stroke prevention in patients with atrial fibrillation. MEASUREMENTS: Prescription drug expenditures were calculated for each patient in the cohort under three conditions: the 2006 AARP-endorsed prescription drug plan, the Medicare standard benefit, and no prescription drug coverage. RESULTS: Total prescriptions drug costs were lower under the AARP plan, yet patients paid a similar percentage of total costs under the AARP plan and the Medicare standard benefit. Using different cost assessments, 27% to 46% of patients entered the "doughnut hole" in the AARP plan, and 3% to 11% emerged to receive catastrophic coverage. CONCLUSION: Both the AARP-sponsored and standard Medicare Part D prescription drug benefit programs offer significant savings to enrollees. A greater savings is achieved under the private AARP drug insurance plan, largely due to greater discounts reflected in the negotiated drug prices. A substantial portion of enrollees enter but do not emerge from the coverage gap.

Original languageEnglish (US)
Pages (from-to)1038-1043
Number of pages6
JournalJournal of the American Geriatrics Society
Volume55
Issue number7
DOIs
StatePublished - Jul 2007
Externally publishedYes

Fingerprint

Medicare Part D
Drug Costs
Prescription Drugs
Medicare
Atrial Fibrillation
Population
Pharmaceutical Services Insurance
Costs and Cost Analysis
Cost Savings
Health Expenditures
Prescriptions
Cohort Studies
Stroke
Pharmaceutical Preparations

Keywords

  • Atrial fibrillation
  • Drug
  • Insurance
  • Medicare Part D
  • Pharmaceutical services
  • Prescription

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

The new medicare part D prescription drug benefit : An estimation of its effect on prescription drug costs in a medicare population with atrial fibrillation. / Evans-Molina, Carmella; Regan, Susan; Henault, Lori E.; Hylek, Elaine M.; Schwartz, Gregory R.

In: Journal of the American Geriatrics Society, Vol. 55, No. 7, 07.2007, p. 1038-1043.

Research output: Contribution to journalArticle

@article{099f742f427545d284580f0dbde20099,
title = "The new medicare part D prescription drug benefit: An estimation of its effect on prescription drug costs in a medicare population with atrial fibrillation",
abstract = "OBJECTIVES: To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients. DESIGN: Inception cohort study. SETTING: An academic medical center. PARTICIPANTS: Four hundred seventy-two patients aged 65 and older who were followed as part of a larger study assessing stroke prevention in patients with atrial fibrillation. MEASUREMENTS: Prescription drug expenditures were calculated for each patient in the cohort under three conditions: the 2006 AARP-endorsed prescription drug plan, the Medicare standard benefit, and no prescription drug coverage. RESULTS: Total prescriptions drug costs were lower under the AARP plan, yet patients paid a similar percentage of total costs under the AARP plan and the Medicare standard benefit. Using different cost assessments, 27{\%} to 46{\%} of patients entered the {"}doughnut hole{"} in the AARP plan, and 3{\%} to 11{\%} emerged to receive catastrophic coverage. CONCLUSION: Both the AARP-sponsored and standard Medicare Part D prescription drug benefit programs offer significant savings to enrollees. A greater savings is achieved under the private AARP drug insurance plan, largely due to greater discounts reflected in the negotiated drug prices. A substantial portion of enrollees enter but do not emerge from the coverage gap.",
keywords = "Atrial fibrillation, Drug, Insurance, Medicare Part D, Pharmaceutical services, Prescription",
author = "Carmella Evans-Molina and Susan Regan and Henault, {Lori E.} and Hylek, {Elaine M.} and Schwartz, {Gregory R.}",
year = "2007",
month = "7",
doi = "10.1111/j.1532-5415.2007.01285.x",
language = "English (US)",
volume = "55",
pages = "1038--1043",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Wiley-Blackwell",
number = "7",

}

TY - JOUR

T1 - The new medicare part D prescription drug benefit

T2 - An estimation of its effect on prescription drug costs in a medicare population with atrial fibrillation

AU - Evans-Molina, Carmella

AU - Regan, Susan

AU - Henault, Lori E.

AU - Hylek, Elaine M.

AU - Schwartz, Gregory R.

PY - 2007/7

Y1 - 2007/7

N2 - OBJECTIVES: To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients. DESIGN: Inception cohort study. SETTING: An academic medical center. PARTICIPANTS: Four hundred seventy-two patients aged 65 and older who were followed as part of a larger study assessing stroke prevention in patients with atrial fibrillation. MEASUREMENTS: Prescription drug expenditures were calculated for each patient in the cohort under three conditions: the 2006 AARP-endorsed prescription drug plan, the Medicare standard benefit, and no prescription drug coverage. RESULTS: Total prescriptions drug costs were lower under the AARP plan, yet patients paid a similar percentage of total costs under the AARP plan and the Medicare standard benefit. Using different cost assessments, 27% to 46% of patients entered the "doughnut hole" in the AARP plan, and 3% to 11% emerged to receive catastrophic coverage. CONCLUSION: Both the AARP-sponsored and standard Medicare Part D prescription drug benefit programs offer significant savings to enrollees. A greater savings is achieved under the private AARP drug insurance plan, largely due to greater discounts reflected in the negotiated drug prices. A substantial portion of enrollees enter but do not emerge from the coverage gap.

AB - OBJECTIVES: To compare prescription drug cost savings under the most commonly selected Medicare Part D prescription plan in 2006 with savings under the Medicare standard benefit and with drug costs assuming no coverage in an elderly cohort of patients. DESIGN: Inception cohort study. SETTING: An academic medical center. PARTICIPANTS: Four hundred seventy-two patients aged 65 and older who were followed as part of a larger study assessing stroke prevention in patients with atrial fibrillation. MEASUREMENTS: Prescription drug expenditures were calculated for each patient in the cohort under three conditions: the 2006 AARP-endorsed prescription drug plan, the Medicare standard benefit, and no prescription drug coverage. RESULTS: Total prescriptions drug costs were lower under the AARP plan, yet patients paid a similar percentage of total costs under the AARP plan and the Medicare standard benefit. Using different cost assessments, 27% to 46% of patients entered the "doughnut hole" in the AARP plan, and 3% to 11% emerged to receive catastrophic coverage. CONCLUSION: Both the AARP-sponsored and standard Medicare Part D prescription drug benefit programs offer significant savings to enrollees. A greater savings is achieved under the private AARP drug insurance plan, largely due to greater discounts reflected in the negotiated drug prices. A substantial portion of enrollees enter but do not emerge from the coverage gap.

KW - Atrial fibrillation

KW - Drug

KW - Insurance

KW - Medicare Part D

KW - Pharmaceutical services

KW - Prescription

UR - http://www.scopus.com/inward/record.url?scp=34347404691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347404691&partnerID=8YFLogxK

U2 - 10.1111/j.1532-5415.2007.01285.x

DO - 10.1111/j.1532-5415.2007.01285.x

M3 - Article

C2 - 17608876

AN - SCOPUS:34347404691

VL - 55

SP - 1038

EP - 1043

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 7

ER -